Congenital athymia treatment Rethymic (RVT-802) is still under FDA review, with an 8 October user fee goal date, but FDA announced the regenerative medicine product had earned a rare pediatric disease priority review voucher; agency says the notice was published in error and will be withdrawn.

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

The Swiss group has posted a solid if unspectacular set of six-month results and is "working on a number of opportunities" that should close by the end of the year, according to its CFO.

The global market for robotically assisted surgical devices will reach $11.5bn by 2025 as system improvements drive sales.